 |
5 Products |  |
0 Diseases | | 5 Products |
|
3 Trials |  |
266 News |  |
| «123» |
- | Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Enrollment change: Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD) (clinicaltrials.gov) - Oct 30, 2018
P1/2, N=20, Completed, Sponsor: Fred Hutchinson Cancer Research Center
N=14 --> 20
- | Cytogam (cytomegalovirus immune globulin intravenous(human)) / Kamada
Enrollment closed, Trial primary completion date: A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV) (clinicaltrials.gov) - Jun 14, 2018
P3, N=800, Active, not recruiting, Sponsor: The George Washington University Biostatistics Center
N=14 --> 20 Recruiting --> Active, not recruiting | Trial primary completion date: May 2018 --> Nov 2018
- Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD (clinicaltrials.gov) - Jun 3, 2018
P2/3, N=1, Terminated, Sponsor: Baxalta now part of Shire
Recruiting --> Active, not recruiting | Trial primary completion date: May 2018 --> Nov 2018 N=168 --> 1 | Trial completion date: Jul 2019 --> May 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2018 --> May 2018; The decision to discontinue the study was based on business reasons.
- | Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Trial completion date, Trial primary completion date: GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study (clinicaltrials.gov) - Apr 27, 2018
P3, N=36, Recruiting, Sponsor: Baxalta now part of Shire
N=168 --> 1 | Trial completion date: Jul 2019 --> May 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2018 --> May 2018; The decision to discontinue the study was based on business reasons. Trial completion date: May 2019 --> May 2020 | Trial primary completion date: May 2019 --> May 2020
- OctaAlpha1 / Octapharma
Enrollment change, Trial withdrawal: Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency (clinicaltrials.gov) - Apr 10, 2018
P2, N=0, Withdrawn, Sponsor: Octapharma
Trial completion date: May 2019 --> May 2020 | Trial primary completion date: May 2019 --> May 2020 N=40 --> 0 | Not yet recruiting --> Withdrawn
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Glassia (alpha1-proteinase inhibitor (Human)) / Takeda
Trial primary completion date: Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant (clinicaltrials.gov) - Mar 21, 2018
P2, N=20, Recruiting, Sponsor: Massachusetts General Hospital
N=40 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Jan 2018 --> Dec 2019
- ||||| Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Enrollment closed: A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD (clinicaltrials.gov) - Mar 14, 2018
P2/3, N=168, Active, not recruiting, Sponsor: Baxalta now part of Shire
Trial primary completion date: Jan 2018 --> Dec 2019 Suspended --> Active, not recruiting
- | Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Trial completion date, Trial primary completion date: GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study (clinicaltrials.gov) - Feb 23, 2018
P3, N=36, Recruiting, Sponsor: Baxalta now part of Shire
Suspended --> Active, not recruiting Trial primary completion date: Feb 2018 --> May 2019 | Trial completion date: Feb 2018 --> May 2019
- | Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Journal: Response of Steroid-Refractory Acute GVHD to α1-Anti-Trypsin. (Pubmed Central) - Feb 18, 2018
In a phase I/II open-label single-center study, we administered AAT (Glassia; Baxalta/Kamada, New Ziona, Israel) as salvage therapy to 12 patients with steroid-refractory acute graft-versus-host disease (GVHD)...These findings show that AAT is well tolerated and has efficacy in the treatment of steroid-refractory severe acute GvHD. Further studies are warranted.
- | Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Enrollment closed: Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation (clinicaltrials.gov) - Feb 5, 2018
P2, N=30, Active, not recruiting, Sponsor: Kamada, Ltd.
Further studies are warranted. Recruiting --> Active, not recruiting
- | KedRAB (human rabies immune globulin) / Kamada, Kedrion
Enrollment open, Trial primary completion date: Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies (clinicaltrials.gov) - Feb 5, 2018
P3, N=30, Recruiting, Sponsor: Kamada, Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2018 --> Apr 2019
- |||| Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Trial completion: Phase II Study to Evaluate the Efficacy and Safety of Glassia (clinicaltrials.gov) - Feb 1, 2018
P2, N=71, Completed, Sponsor: Kamada, Ltd.
Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2018 --> Apr 2019 Active, not recruiting --> Completed
- | OctaAlpha1 / Octapharma
New P2 trial: Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency (clinicaltrials.gov) - Dec 28, 2017
P2, N=40, Not yet recruiting, Sponsor: Octapharma
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion, Enrollment change, Trial initiation date: Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch (clinicaltrials.gov) - Dec 20, 2017
P3, N=56, Completed, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Recruiting --> Completed | N=110 --> 56 | Initiation date: Jan 2006 --> Jan 2007
- | Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Trial primary completion date: GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study (clinicaltrials.gov) - Sep 11, 2017
P3, N=36, Recruiting, Sponsor: Baxalta US Inc.
Recruiting --> Completed | N=110 --> 56 | Initiation date: Jan 2006 --> Jan 2007 Trial primary completion date: Sep 2017 --> Feb 2018
- ||||| Bonsity (teriparatide biosimilar) / China NT Pharma, Alvogen, Kamada, Ligand
Enrollment closed: A Comparison of PF708 and Forteo in Osteoporosis Patients (clinicaltrials.gov) - Aug 23, 2017
P3, N=168, Active, not recruiting, Sponsor: Pfenex, Inc
Trial primary completion date: Sep 2017 --> Feb 2018 Recruiting --> Active, not recruiting
- || Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Clinical: A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD (clinicaltrials.gov) - Jul 11, 2017
P2/3, N=168, Suspended, Sponsor: Baxalta US Inc.
Recruiting --> Active, not recruiting Initiation date: Nov 2016 --> Apr 2017 | Recruiting --> Suspended
- Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
New trial: Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT) (clinicaltrials.gov) - Jun 1, 2017
P=N/A, N=0, Available, Sponsor: Impatients N.V. trading as myTomorrows
- | Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Trial completion, Trial primary completion date: Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD) (clinicaltrials.gov) - May 24, 2017
P1/2, N=14, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Initiation date: Nov 2016 --> Apr 2017 | Recruiting --> Suspended Active, not recruiting --> Completed | Trial primary completion date: Jul 2017 --> Jan 2017
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Glassia (alpha1-proteinase inhibitor (Human)) / Takeda
Enrollment open: Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant (clinicaltrials.gov) - Apr 20, 2017
P2, N=20, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | Trial primary completion date: Jul 2017 --> Jan 2017 Not yet recruiting --> Recruiting
- | Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Enrollment closed, Enrollment change: Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD) (clinicaltrials.gov) - Mar 8, 2017
P1/2, N=14, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=24 --> 14
- |||||||||| Bonsity (teriparatide biosimilar) / China NT Pharma, Alvogen, Kamada, Ligand
New P3 trial: A Comparison of PF708 and Forteo in Osteoporosis Patients (clinicaltrials.gov) - Dec 23, 2016
P3, N=168, Recruiting, Sponsor: Pfenex, Inc
- |||||| Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Clinical: A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD (clinicaltrials.gov) - Dec 15, 2016
P2/3, N=168, Recruiting, Sponsor: Baxalta US Inc.
Recruiting --> Active, not recruiting | N=24 --> 14 Not yet recruiting --> Recruiting
- Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Trial primary completion date: Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD) (clinicaltrials.gov) - Nov 23, 2016
P1/2, N=24, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Jul 2017
- |||||||||| Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Clinical: A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD (clinicaltrials.gov) - Nov 7, 2016
P2/3, N=168, Not yet recruiting, Sponsor: Baxalta US Inc.
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Glassia (alpha1-proteinase inhibitor (Human)) / Takeda
Trial initiation date: Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant (clinicaltrials.gov) - Oct 31, 2016
P2, N=20, Not yet recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Dec 2016 --> Jul 2017 Initiation date: May 2016 --> Jan 2017
- ||| KedRAB (human rabies immune globulin) / Kamada, Kedrion
New P3 trial: Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies (clinicaltrials.gov) - Sep 23, 2016
P3, N=30, Not yet recruiting, Sponsor: Kamada, Ltd.
- ||| Bonsity (teriparatide biosimilar) / China NT Pharma, Alvogen, Kamada, Ligand
Trial completion: A Comparison Study of PF708 and Forteo in Healthy Subjects (clinicaltrials.gov) - Aug 4, 2016
P1, N=70, Completed, Sponsor: Pfenex, Inc
Initiation date: May 2016 --> Jan 2017 Active, not recruiting --> Completed
- ||| Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Enrollment closed, Phase classification, Enrollment change, Trial primary completion date: Phase II Study to Evaluate the Efficacy and Safety of Glassia (clinicaltrials.gov) - Jun 10, 2016
P2, N=71, Active, not recruiting, Sponsor: Kamada, Ltd.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Phase classification: P2/3 --> P2 | N=192 --> 71 | Trial primary completion date: Apr 2016 --> Jan 2017
- | Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Enrollment open: Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation (clinicaltrials.gov) - Jun 10, 2016
P2, N=30, Recruiting, Sponsor: Kamada, Ltd.
Recruiting --> Active, not recruiting | Phase classification: P2/3 --> P2 | N=192 --> 71 | Trial primary completion date: Apr 2016 --> Jan 2017 Not yet recruiting --> Recruiting
- Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Trial primary completion date: Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD) (clinicaltrials.gov) - May 25, 2016
P1/2, N=24, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2016 --> Dec 2016
- || Bonsity (teriparatide biosimilar) / China NT Pharma, Alvogen, Kamada, Ligand
Enrollment closed: A Comparison Study of PF708 and Forteo in Healthy Subjects (clinicaltrials.gov) - May 4, 2016
P1, N=70, Active, not recruiting, Sponsor: Pfenex, Inc
Trial primary completion date: Jun 2016 --> Dec 2016 Recruiting --> Active, not recruiting
- |||| Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda, Aralast NP (alpha 1-antitrypsin) / Omni Bio Pharma, Takeda
Enrollment open: Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency (clinicaltrials.gov) - Apr 29, 2016
P4, N=138, Recruiting, Sponsor: Baxalta US Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda, Aralast NP (alpha 1-antitrypsin) / Omni Bio Pharma, Takeda
New P4 trial: Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency (clinicaltrials.gov) - Mar 30, 2016
P4, N=138, Not yet recruiting, Sponsor: Baxalta US Inc.
- | Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Enrollment open: GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study (clinicaltrials.gov) - Mar 14, 2016
P3, N=36, Recruiting, Sponsor: Baxalta US Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Cytogam (cytomegalovirus immune globulin intravenous(human)) / Kamada
Trial completion: Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection (clinicaltrials.gov) - Feb 16, 2016
P4, N=40, Completed, Sponsor: Medical University of South Carolina
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Bonsity (teriparatide biosimilar) / China NT Pharma, Alvogen, Kamada, Ligand
New P1 trial: A Comparison Study of PF708 and Forteo in Healthy Subjects (clinicaltrials.gov) - Jan 15, 2016
P1, N=70, Recruiting, Sponsor: Pfenex, Inc
- | Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Trial initiation date: GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study (clinicaltrials.gov) - Dec 30, 2015
P3, N=36, Not yet recruiting, Sponsor: Baxalta US Inc.
Active, not recruiting --> Completed Initiation date: Sep 2015 --> Feb 2016
- Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Trial primary completion date: Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD) (clinicaltrials.gov) - Nov 26, 2015
P1/2, N=24, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Initiation date: Sep 2015 --> Feb 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- | Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
New P2 trial: Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation (clinicaltrials.gov) - Nov 26, 2015
P2, N=30, Not yet recruiting, Sponsor: Kamada, Ltd.
- ||| Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
New P3 trial: GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study (clinicaltrials.gov) - Aug 18, 2015
P3, N=36, Not yet recruiting, Sponsor: Baxalta US Inc.
- | Cytogam (cytomegalovirus immune globulin intravenous(human)) / Kamada
Trial completion: Panel Reactive Antibody (PRA) Reduction in Sensitized Patients Awaiting Renal Transplantation (clinicaltrials.gov) - Jun 29, 2015
P4, N=26, Completed, Sponsor: Tampa General Hospital
Trial primary completion date: Dec 2015 --> Jun 2016 Active, not recruiting --> Completed
- Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Trial initiation date: Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD) (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=24, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Initiation date: Feb 2012 --> Nov 2013
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Glassia (alpha1-proteinase inhibitor (Human)) / Takeda
New P2 trial: Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant (clinicaltrials.gov) - Jun 6, 2015
P2, N=20, Not yet recruiting, Sponsor: Massachusetts General Hospital
- Prolastin-C (human alpha1-proteinase inhibitor IV) / Grifols, OrphanPacific
Enrollment change, Trial termination: Safety and Efficacy of (?1Proteinase Inhibitor, ?1PI) in HIV Disease (clinicaltrials.gov) - Dec 10, 2014
P2/3, N=12, Terminated, Sponsor: Institute for Human Genetics and Biochemistry
Initiation date: Feb 2012 --> Nov 2013 N=20 --> 12 | Recruiting --> Terminated; Blinded review of the data suggested no significant diferences in outcomes.
- ||||| KedRAB (human rabies immune globulin) / Kamada, Kedrion
Enrollment closed, Trial primary completion date, Head-to-Head: KAMRAB-003: Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects (clinicaltrials.gov) - Aug 1, 2014
P2/3, N=118, Active, not recruiting, Sponsor: Kamada, Ltd.
N=20 --> 12 | Recruiting --> Terminated; Blinded review of the data suggested no significant diferences in outcomes. Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Aug 2014
- | Prolastin-C (human alpha1-proteinase inhibitor IV) / Grifols, OrphanPacific
Trial primary completion date: Safety and Efficacy of (?1Proteinase Inhibitor, ?1PI) in HIV Disease (clinicaltrials.gov) - Jun 27, 2014
P2/3, N=20, Recruiting, Sponsor: Institute for Human Genetics and Biochemistry
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Aug 2014 Trial primary completion date: Mar 2013 --> Jul 2014
- ||||| Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Trial initiation date: Phase II Study to Evaluate the Efficacy and Safety of Glassia (clinicaltrials.gov) - Mar 29, 2014
P2/3, N=192, Recruiting, Sponsor: Kamada, Ltd.
Trial primary completion date: Mar 2013 --> Jul 2014 Initiation date: Dec 2013 --> Mar 2014
- |||||| Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Enrollment open: Phase II Study to Evaluate the Efficacy and Safety of Glassia (clinicaltrials.gov) - Mar 29, 2014
P2/3, N=192, Recruiting, Sponsor: Kamada, Ltd.
Initiation date: Dec 2013 --> Mar 2014 Not yet recruiting --> Recruiting
- HepaGam B (hepatitis B immune globulin intravenous (human)) / Kamada
Trial completion: Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients (clinicaltrials.gov) - Mar 20, 2014
P4, N=10, Completed, Sponsor: Georgetown University
Not yet recruiting --> Recruiting Recruiting --> Completed